|Moderated By: Ruffian -- (Moderated) -- Started: 3/31/2006 12:41:58 PM Revision History|
ADVENTRX Pharmaceuticals, Inc. operates as a biopharmaceutical research and development company. The company focuses on new technologies for anticancer and antiviral treatments, which address drug metabolism, toxicity, bioavailability, or resistance problems. Its lead product includes CoFactor, a folate-based biomodulator drug, which is used for the treatment of metastatic GI and breast cancers, metastatic colorectal cancer, and metastatic pancreatic cancer. CoFactor is tested with 5-FU in a U.S. based Phase II and an EU-based Phase IIb clinical trial as a first line treatment of metastatic colorectal cancer. In addition, CoFactor received clearance under a special protocol assessment from the U.S. FDA for a Phase III pivotal clinical trial for metastatic colorectal cancer. ADVENTRX Pharmaceuticals also has an exclusive license from the University of Southern California to develop and commercialize CoFactor. The company, formerly known as Biokeys Pharmaceuticals, Inc., was organized in 1995 and changed its name to ADVENTRX Pharmaceuticals, Inc. in 2003. ADVENTRX Pharmaceuticals is based in San Diego, California.
Copyright © 1995-2013 Knight Sac Media. All rights reserved.